Pike Therapeutics Inc.

VANCOUVER, A1 · Founded 2019 · Biotech · Private

Transdermal drug delivery technology platform

Claim this profile

Follows are private to you and power your alerts

Updated · piketx.com

Sector
Biotech
Headquarters
VANCOUVER, A1
Founded
2019
Latest Form D
$100K, Sep 2023
Total capital
$275K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$275K
2 Form D · last Sep 2023
38 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
5
25 pending · first 2024
Rank in peer group#38 of 342

Capital timeline

202120222023FEDERAL ↑EQUITY ↓Cumulative $275K1st Form D$175K2nd Form D$100K
202120222023FEDERAL ↑EQUITY ↓Cumulative $275K1st Form D$175K2nd Form D$100K

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$100K
  • Private capital raisedForm D · SEC · 1st filing$175K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#38 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • BRADLEY MILESExecutive Officer, DirectorNamed in SEC Form D filings
  • IAN FODIEExecutive Officer, DirectorNamed in SEC Form D filings
  • MARK PURDYDirectorNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 30
  • PendingTransdermal Pharmaceutical Formulations for the Treatment of Multiple SclerosisUSPTOApplication 19399983
  • PendingTransdermal Delivery of TetrahydrocannabinolUSPTOApplication 19083851
  • PendingTransdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic PainUSPTOApplication 19087734
Show all 30 patent records
  • Transdermal Pharmaceutical Formulations for the Treatment of Multiple SclerosisMar 19, 2026 · Application 19399983Pending
  • Transdermal Delivery of TetrahydrocannabinolOct 9, 2025 · Application 19083851Pending
  • Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic PainAug 7, 2025 · Application 19087734Pending
  • Pharmaceutical Compositions and Methods for Treating Parkinson's DiseaseJun 12, 2025 · Application 19053616Pending
  • Transdermal Delivery of TetrahydrocannabinolApr 8, 2025 · US 12,268,699Granted
  • Pharmaceutical Composition and Method for Treating Seizure DisordersFeb 13, 2025 · Application 18929710Pending
  • Pharmaceutical Composition And Method For Treating Seizure DisordersJan 7, 2025 · US 12,186,280Granted
  • Transdermal Delivery Of CannabidiolOct 22, 2024 · US 12,121,617Granted
  • Transdermal Delivery Of CannabidiolSep 24, 2024 · US 12,097,293Granted
  • Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Apixaban and Other Direct Oral AnticoagulantsSep 12, 2024 · Application 18594497Pending
  • Pharmaceutical Composition And Method For Treating Seizure DisordersAug 8, 2024 · Application 18629364Pending
  • Pharmaceutical Composition And Method For Treating Seizure DisordersJun 25, 2024 · US 12,016,829Granted
  • Continuous Drug Delivery Systems and MethodsJan 25, 2024 · Application 18224183Pending
  • Transdermal Micro-dosing Delivery Of Pharmaceutical AgentsFeb 23, 2023 · Application 17879846Pending
  • Transdermal Pharmaceutical Formulations For The Treatment Of Chronic PainNov 3, 2022 · Application 17725593Pending
  • Transdermal Pharmaceutical Formulations For The Treatment Of CancerJun 9, 2022 · Application 17540475Pending
  • Transdermal Pharmaceutical Formulations Of Nabilone Alone And In Combination With CannabinoidsFeb 17, 2022 · Application 17401598Pending
  • Pharmaceutical Compositions And Methods For Treating Parkinson's DiseaseFeb 17, 2022 · Application 17401374Pending
  • Transdermal Pharmaceutical Formulations For The Treatment Of Multiple SclerosisJan 6, 2022 · Application 17365060Pending
  • Transdermal And/or Topical, Pharmaceutical Formulations Comprising Cannabidiol And/or Tetrahydrocannabinol For The Treatment Of Chronic PainNov 11, 2021 · Application 17235314Pending
  • Transdermal Micro-dosing Delivery Of Psychedelics DerivativesOct 21, 2021 · Application 17231553Pending
  • Transdermal Micro-dosing Delivery Of Pharmaceutical AgentsApplication 63324288Pending
  • Continuous Drug Delivery Systems And MethodsApplication 63391004Pending
  • Transdermal Drug Delivery Systems For Administration Of A Therapeutically Effective Amount Of Apixaban And Other Direct Oral AnticoagulantsApplication 63450515Pending
  • Transdermal Pharmaceutical Formulations Of Nabilone Alone And In Combination With CannabinoidsApplication 63066386Pending
  • Transdermal Pharmaceutical Formulations For The Treatment Of Multiple SclerosisApplication 63046855Pending
  • Pharmaceutical Compositions And Methods For Treating Parkinson's DiseaseApplication 63229021Pending
  • Transdermal And/or Topical Pharmaceutical Formulations Comprising Cannabidiol And/or Tetrahydrocannabinol For The Treatment Of Chronic PainApplication 63012428Pending
  • Transdermal Pharmaceutical Formulations For The Treatment Of Chronic PainApplication 63177981Pending
  • Transdermal Micro-dosing Delivery Of Pharmaceutical AgentsApplication 63229015Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .